Sept. 27, 2018 from noon to 1 p.m.
Seminar Room B – 2nd Floor
Hess Center for Science & Medicine
1470 Madison Avenue, New York, NY
- David S. Karow, MD, PhD
- Interim Chief Executive Officer
- Human Longevity, Inc.
- San Diego, California
Despite the enormous cost of U.S. healthcare (over $3 trillion in 2016),
one-third of individuals aged 50-75 in the United States die prematurely
from age-related chronic diseases. The overwhelming cost of the current
health system is due, at least partly, to its tendency to be more reactive
than proactive, and the usage of medical imaging and clinical tests has
classically focused on patient cohorts that already display disease
We present a unique platform of deep quantitative multimodal
phenotyping that provides a comprehensive, predictive, preventive, and
personalized assessment of an individual's health status. The offered
multimodal assays include whole genome sequencing (WGS), advanced
imaging, metagenomic sequencing, metabolome, electrocardiogram, and
clinical labs as well as detailed personal and family medical history.
Highlighting the value of using a multimodal approach, we show how we
have used these data to create an integrated risk report for an
individual’s risk of short-term cognitive decline and lifetime risk of
developing dementia. We leveraged known genetic variants associated
with the risk of Alzheimer’s and features from structural magnetic
resonance images of the brain (MRI) including surface area, thickness,
and volume of regions of interest, as well as demographics and
modifiable risk factors. In all cases, the combination of MRI and genetics
data improved performance in the prediction of dementia progression
over either element alone.